2022, July

Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted in SEK 20 million to a valuation of SEK 378 million after the issue. The issue consists of SEK 15 million in a rights issue to existing owners and a directed new issue of SEK 5 million to the Swedish life science focused

2022, June

Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension Attgeno AB today announced that it has received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start a phase 2 clinical trial of its lead drug candidate Supernitro as a potentially lifesaving treatment for patients with acute pulmonary hypertension after cardiac surgery. Read More

2022, May

Attgeno reports on the completed Phase I study of the drug candidate, Supernitro The last of 38 study participants were treated with Supernitro on 18 May, and the substance has shown good safety and tolerability. No unexpected side effects have been reported. At a higher dose and longer treatment, the expected side effects have been noted in line with the substance mechanism of action – vasodilation through the release of nitric oxide (NO). Read more

2021, Jul

Attgeno appoints Björn Westberg as CFO Attgeno AB announces today that Björn Westberg has been appointed CFO and member of the management team at Attgeno. Björn most recently comes from a role as CFO at Enea AB (publ). Read more

2021, Mar

Attgeno reports first healthy volunteers dosed with Supernitro in phase 1 trial Attgeno AB today announced that the first 8 healthy volunteers have been successfully dosed in a phase 1 clinical study with the company’s lead drug candidate, Supernitro. The trial continues according to the clinical protocol and will include up to 48 healthy volunteers. Read more